|
1
|
Neri F, Dettori D, Incarnato D, Krepelova
A, Rapelli S, Maldotti M, Parlato C, Paliogiannis P and Oliviero S:
TET1 is a tumour suppressor that inhibits colon cancer growth by
derepressing inhibitors of the WNT pathway. Oncogene. 34:4168–4176.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Slattery ML, Pellatt DF, Mullany LE, Wolff
RK and Herrick JS: Gene expression in colon cancer: A focus on
tumor site and molecular phenotype. Genes Chromosomes Cancer.
54:527–541. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
van Duijnhoven FJ, Bueno-De-Mesquita HB,
Ferrari P, Jenab M, Boshuizen HC, Ros MM, Casagrande C, Tjønneland
A, Olsen A, Overvad K, et al: Fruit, vegetables, and colorectal
cancer risk: The European Prospective Investigation into Cancer and
Nutrition. Am J Clin Nutr. 89:1441–1452. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
McCormack VA and Boffetta P: Today's
lifestyles, tomorrow's cancers: Trends in lifestyle risk factors
for cancer in low- and middle-income countries. Ann Oncol.
22:2349–2357. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kan JY, Hsu YL, Chen YH, Chen TC, Wang JY
and Kuo PL: Gemifloxacin, a fluoroquinolone antimicrobial drug,
inhibits migration and invasion of human colon cancer cells. Biomed
Res Int. 2013:1597862013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Abbadessa B, Agnew J, Bonomo G, et al:
Overall survival is negatively impacted by postoperative
complications following curative resection of rectal cancer but not
colon cancer. Dis Colon Rectum. 56:E261–E262. 2013.
|
|
7
|
Leffler H, Carlsson S, Hedlund M, Qian Y
and Poirier F: Introduction to galectins. Glycoconj J. 19:433–440.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wiersma VR, de Bruyn M, Helfrich W and
Bremer E: Therapeutic potential of Galectin-9 in human disease. Med
Res Rev. 33:(Suppl 1). E102–E126. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Matsumoto R, Hirashima M, Kita H and
Gleich GJ: Biological activities of ecalectin: A novel
eosinophil-activating factor. J Immunol. 168:1961–1967. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Matsumoto R, Matsumoto H, Seki M, Hata M,
Asano Y, Kanegasaki S, Stevens RL and Hirashima M: Human ecalectin,
a variant of human galectin-9, is a novel eosinophil
chemoattractant produced by T lymphocytes. J Biol Chem.
273:16976–16984. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Niwa H, Satoh T, Matsushima Y, Hosoya K,
Saeki K, Niki T, Hirashima M and Yokozeki H: Stable form of
galectin-9, a Tim-3 ligand, inhibits contact hypersensitivity and
psoriatic reactions: A potent therapeutic tool for Th1- and/or
Th17-mediated skin inflammation. Clin Immunol. 132:184–194. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Abedin MJ, Kashio Y, Seki M, Nakamura K
and Hirashima M: Potential roles of galectins in myeloid
differentiation into three different lineages. J Leukoc Biol.
73:650–656. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kashio Y, Nakamura K, Abedin MJ, Seki M,
Nishi N, Yoshida N, Nakamura T and Hirashima M: Galectin-9 induces
apoptosis through the calcium-calpain-caspase-1 pathway. J Immunol.
170:3631–3636. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nobumoto A, Nagahara K, Oomizu S, Katoh S,
Nishi N, Takeshita K, Niki T, Tominaga A, Yamauchi A and Hirashima
M: Galectin-9 suppresses tumor metastasis by blocking adhesion to
endothelium and extracellular matrices. Glycobiology. 18:735–744.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang ZY, Dong JH, Chen YW, Wang XQ, Li
CH, Wang J, Wang GQ, Li HL and Wang XD: Galectin-9 acts as a
prognostic factor with antimetastatic potential in hepatocellular
carcinoma. Asian Pac J Cancer Prev. 13:2503–2509. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kozak M: Faulty old ideas about
translational regulation paved the way for current confusion about
how microRNAs function. Gene. 423:108–115. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Qu J, Zhao L, Zhang P, Wang J, Xu N, Mi W,
Jiang X, Zhang C and Qu J: MicroRNA-195 chemosensitizes colon
cancer cells to the chemotherapeutic drug doxorubicin by targeting
the first binding site of BCL2L2 mRNA. J Cell Physiol. 230:535–545.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Friedman RC, Farh KK, Burge CB and Bartel
DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome
Res. 19:92–105. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ren XS, Yin MH, Zhang X, Wang Z, Feng SP,
Wang GX, Luo YJ, Liang PZ, Yang XQ, He JX and Zhang BL:
Tumor-suppressive microRNA-449a induces growth arrest and
senescence by targeting E2F3 in human lung cancer cells. Cancer
Lett. 344:195–203. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kasashima K, Nakamura Y and Kozu T:
Altered expression profiles of microRNAs during TPA-induced
differentiation of HL-60 cells. Biochem Biophys Res Commun.
322:403–410. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
McManus MT: MicroRNAs and cancer. Semin
Cancer Biol. 13:253–258. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Miao J, Wu S, Peng Z, Tania M and Zhang C:
MicroRNAs in osteosarcoma: Diagnostic and therapeutic aspects.
Tumour Biol. 34:2093–2098. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cimmino A, Calin GA, Fabbri M, Iorio MV,
Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M, et
al: miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl
Acad Sci USA. 102:13944–13949. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yang Q, Jiang W, Zhuang C, Geng Z, Hou C,
Huang D, Hu L and Wang X: microRNA-22 downregulation of galectin-9
influences lymphocyte apoptosis and tumor cell proliferation in
liver cancer. Oncol Rep. 34:1771–1778. 2015.PubMed/NCBI
|
|
27
|
Thijssen VL, Hulsmans S and Griffioen AW:
The galectin profile of the endothelium: Altered expression and
localization in activated and tumor endothelial cells. Am J Pathol.
172:545–553. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Türeci O, Schmitt H, Fadle N, Pfreundschuh
M and Sahin U: Molecular definition of a novel human galectin which
is immunogenic in patients with Hodgkin's disease. J Biol Chem.
272:6416–6422. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu Z, Han H, He X, Li S, Wu C, Yu C and
Wang S: Expression of the galectin-9-Tim-3 pathway in glioma
tissues is associated with the clinical manifestations of glioma.
Oncol Lett. 11:1829–1834. 2016.PubMed/NCBI
|
|
30
|
Heusschen R, Griffioen AW and Thijssen VL:
Galectin-9 in tumor biology: A jack of multiple trades. Biochim
Biophys Acta. 1836:177–185. 2013.PubMed/NCBI
|
|
31
|
Saita N, Goto E, Yamamoto T, Cho I,
Tsumori K, Kohrogi H, Maruo K, Ono T, Takeya M, Kashio Y, et al:
Association of galectin-9 with eosinophil apoptosis. Int Arch
Allergy Immunol. 128:42–50. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kobayashi T, Kuroda J, Ashihara E, Oomizu
S, Terui Y, Taniyama A, Adachi S, Takagi T, Yamamoto M, Sasaki N,
et al: Galectin-9 exhibits anti-myeloma activity through JNK and
p38 MAP kinase pathways. Leukemia. 24:843–850. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Iorio MV and Croce CM: MicroRNAs in
cancer: Small molecules with a huge impact. J Clin Oncol.
27:5848–5856. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang YW, Shi DB, Chen X, Gao C and Gao P:
Clinicopathological significance of microRNA-214 in gastric cancer
and its effect on cell biological behaviour. PLoS One.
9:e913072014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liu CL, Iqbal J, Teruya-Feldstein J, Shen
Y, Dabrowska MJ, Dybkaer K, Lim MS, Piva R, Barreca A, Pellegrino
E, et al: microRNA expression profiling identifies molecular
signatures associated with anaplastic large cell lymphoma. Blood.
122:2083–2092. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Shoshan E, Mobley AK, Braeuer RR, Kamiya
T, Huang L, Vasquez ME, Salameh A, Lee HJ, Kim SJ, Ivan C, et al:
Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma
growth and metastasis. Nat Cell Biol. 17:311–321. 2015. View Article : Google Scholar : PubMed/NCBI
|
